Business
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced it has entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC)
About this update from Hercules Capital, Inc.
[{"type":"image","alt":"Dyne Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dyne Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nro7S6xW_IUN_DBx15qegw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39","width":300,"height":91}},"lazy":false},{"type":"text","content":"- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points -","length":141,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced it has entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction strengthens the company’s balance sheet as it advances DYNE-101 and DYNE-251 through critical clinical and regulatory milestones, for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), respectively.","length":709,"tagName":"p"},{"type":"text","content":"“This non-dilutive financing enhances our ability to advance our DM1 and DMD programs, with potential U.S. Accelerated Approval submissions planned for 2026, and provides strategic flexibility as we focus on strengthening our balance sheet and financial outlook,” said John Cox, president and chief executive officer of Dyne. “With $100 million funded upfront and access to additional capital aligned with clinical, regulatory and commercial progress, we are well-positioned to execute on our plans to deliver functional improvement to the neuromuscular community, as we near a potential US launch in DMD in 2027.”","length":614,"tagName":"p"},{"type":"text","content":"“We are pleased to partner with Dyne to advance important therapeutics that address critical unmet needs,” said R. Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital. “Our financia...